Traws Pharma (NASDAQ:TRAW) Downgraded to “Strong Sell” Rating by Wall Street Zen

Traws Pharma (NASDAQ:TRAW) was downgraded by analysts at Wall Street Zen to a “strong sell” rating in a research report issued to clients and investors on Saturday.

TRAW has been the subject of several other research reports. Weiss Ratings downgraded Traws Pharma from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 15th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Traws Pharma in a research report on Wednesday, May 20th. Finally, LADENBURG THALM/SH SH raised Traws Pharma to a “strong-buy” rating in a research report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $8.00.

Traws Pharma Price Performance

Shares of NASDAQ TRAW opened at $1.46 on Friday. Traws Pharma has a 1-year low of $1.00 and a 1-year high of $3.27. The business has a 50-day moving average of $1.61 and a 200-day moving average of $1.80. The company has a market capitalization of $14.83 million, a price-to-earnings ratio of -0.86 and a beta of 1.47.

Traws Pharma (NASDAQ:TRAW) last issued its earnings results on Friday, May 15th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.39. Research analysts expect that Traws Pharma will post -2.23 EPS for the current fiscal year.

Insider Activity at Traws Pharma

In other Traws Pharma news, major shareholder Orbimed Advisors Llc purchased 597,729 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The shares were acquired at an average price of $1.67 per share, for a total transaction of $998,207.43. Following the completion of the purchase, the insider owned 1,203,250 shares in the company, valued at $2,009,427.50. The trade was a 98.71% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 14.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Two Sigma Investments LP lifted its stake in shares of Traws Pharma by 37.1% in the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after acquiring an additional 5,955 shares in the last quarter. State Street Corp acquired a new position in shares of Traws Pharma in the fourth quarter worth about $29,000. XTX Topco Ltd lifted its stake in shares of Traws Pharma by 294.2% in the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after acquiring an additional 31,502 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Traws Pharma in the fourth quarter worth about $56,000. Finally, Geode Capital Management LLC lifted its stake in shares of Traws Pharma by 41.9% in the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after acquiring an additional 18,213 shares in the last quarter. Institutional investors and hedge funds own 7.95% of the company’s stock.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.